Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
1(20%)
Results Posted
50%(2 trials)

Phase Distribution

Ph phase_1
1
20%
Ph phase_2
4
80%

Phase Distribution

1

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
4(80.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

5

all time

Status Distribution
Active(1)
Completed(4)

Detailed Status

Completed4
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
1
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (20.0%)
Phase 24 (80.0%)

Trials by Status

completed480%
recruiting120%

Recent Activity

1 active trials
Showing 5 of 5
recruitingphase_2

A Study of RSLV-132 in Females With Sjögren's Disease

NCT06440525
completedphase_2

Phase 2 Study of RSLV-132 in Subjects With Long COVID

NCT04944121
completedphase_2

A Study of RSLV-132 in Subjects With Primary Sjogren's Syndrome

NCT03247686
completedphase_2

A Phase 2a of RSLV-132 in Subjects With Systemic Lupus Erythematosus (SLE)

NCT02660944
completedphase_1

Dose Escalation Study of RSLV-132 in Subjects With Systemic Lupus Erythematosus

NCT02194400

Clinical Trials (5)

Showing 5 of 5 trials
NCT06440525Phase 2

A Study of RSLV-132 in Females With Sjögren's Disease

Recruiting
NCT04944121Phase 2

Phase 2 Study of RSLV-132 in Subjects With Long COVID

Completed
NCT03247686Phase 2

A Study of RSLV-132 in Subjects With Primary Sjogren's Syndrome

Completed
NCT02660944Phase 2

A Phase 2a of RSLV-132 in Subjects With Systemic Lupus Erythematosus (SLE)

Completed
NCT02194400Phase 1

Dose Escalation Study of RSLV-132 in Subjects With Systemic Lupus Erythematosus

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5